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Abstract
Background: Different criteria regarding outcome measures in smoking research are used, which can lead to
confusion about study results. Consensus in outcome criteria may enhance the comparability of future studies. This
study aims (1) to provide an overview of tobacco researchers’ considered preferences regarding outcome criteria in
randomized controlled smoking cessation trials, and (2) to identify the extent to which researchers can reach
consensus on the importance of these outcome criteria.
Methods: A three-round online Delphi study was conducted among smoking cessation experts. In the first round, the
most important smoking cessation outcome measures were collected by means of open-ended questions, which were
categorized around self-reported and biochemical validation measures. Experts (n = 17) were asked to name the
outcome measures (as well as their assessment method and ideal follow-up period) that they thought were
important when assessing smoking-related outcomes. In the second (n = 48) and third rounds (n = 37), a list of
outcome measures—identified in the first round—was presented to experts. Asking them to rate the importance
of each measure on a seven-point scale.
Results: Experts reached consensus on several items. For self-reports, experts agreed that prolonged abstinence
(6 or/and 12 months), point prevalence abstinence (7 days), continuous abstinence (6 months), and the number
of cigarettes smoked (7 days) are important outcome measures. Experts reached consensus that biochemical
validation methods should not always be used. The preferred biochemical validation methods were carbon
monoxide (expired air) and cotinine (saliva). Preferred follow-ups included 6 and/or 12 months, with or without
intermediate measurements.
Conclusions: Findings suggest only partial compliance with the Russell standard and that more outcome measures
may be important (including seven-day point-prevalence abstinence, number of cigarettes smoked, and cotinine when
using biochemical validation). This study showed where there is and is not consensus, reflecting the need to develop a
more comprehensive standard. For these purposes we provided suggestions for the Russell 2.0 standard.
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Implications
Despite attempts to develop a standard set of outcome
criteria, such as the Russell standard, studies still use dif-
ferent outcome measures. Consensus on the usefulness
of outcome recommendations can be an important pre-
requisite for the wide implementation of any standard.
Findings suggest that respondents are only partially
compliant with the Russell standard and that more out-
come measures may be important (including seven-day
point-prevalence abstinence, number of cigarettes
smoked, and cotinine when using biochemical valid-
ation). This study provides insight into where there is
and is not consensus on tobacco-related effect measures
in randomized controlled trials, and reflects the need to
develop a more comprehensive standard.
Background
Worldwide, the leading preventable cause of illness (e.g.
lung cancer, respiratory- and cardiovascular diseases)
and pre-mature death remains tobacco smoking.
Smoking accounts for more than six million deaths
every year in the world (via smoking-related diseases)
[1]. More effort needs to be directed towards reducing
smoking prevalence, and evidence-based, comprehensive
tobacco control measures should be implemented [2, 3].
Hence, a wide array of effective interventions for smok-
ing cessation has been developed [4–6].
Most interventions rely on randomized controlled tri-
als [RCTs] for proof of efficacy. In doing so, they utilize
a variety of smoking cessation outcome measures to
evaluate the efficacy of interventions. This may limit the
comparability of study results. Not only are various
smoking cessation outcome measures used, previous lit-
erature has reported arguments for, and empiric evalua-
tions of, specific measures [7, 8]. It seems that measures
can be broadly classified as self-report and biochemical
validation measures [8]. Examples of self-report mea-
sures are point-prevalence abstinence—the percentage of
former smokers who are not smoking for a specific
period of time (e.g. 24 h or 7 days) at the point of assess-
ment—and continuous abstinence (the percentage of
former smokers who remained abstinent since the intro-
duction of an intervention or event) [8]. Examples of
biochemical validation measures are carbon monoxide,
which can be measured in expired air and blood, and co-
tinine, which is the major proximate metabolite of nico-
tine and can be measured in various biological
specimens (e.g. saliva and urine) [9].
Velicer, Prochaska, Rossi, and Snow [7] reviewed out-
come measures for smoking cessation and evaluated sev-
eral self-report measures and biochemical validation
measures. In the literature, self-report measures have
been empirically compared and discussed [8]; several
types of biochemical verification methods have been
discussed as well [9]. Using different outcome measures
(self-report and biochemical validation) may vary the re-
ported abstinence rates more than twofold (e.g. Hurt et
al. [10]). Selection of outcome measures should of
course reflect the chosen study goals, which may lead to
differences in outcomes between studies. However when
possible, common outcome measures should be utilized
in order to increase the comparability of effective inter-
ventions. According to West, Hajek, Stead, and
Stapleton [11], depending on the criteria adopted, the
success rates of trials can differ dramatically. However
studies with differing measures, such as using or not
using biochemical validation, or studies with different
follow-up durations, have been combined in overviews
[12–14]. Some studies report similarities in smoking ces-
sation outcomes, like point-prevalence abstinence vs.
prolonged abstinence, producing similar relative effect
sizes [15]. Other studies, however, show differences in
results, with point-prevalence abstinence producing
smaller effect sizes than prolonged abstinence [16, 17].
Given that smoking cessation studies use different out-
come measures, which limits the comparability and in-
terpretability of their findings, a standard set of criteria
for outcome measures in tobacco smoking research is
needed to enable researchers to uniformly express their
results [11].
Attempts have been made to develop a standard set of
criteria for outcome measures that would be utilized by all
investigators. A workgroup examined outcome measures
used in clinical trials using a literature search in 2003 [16],
resulting in an overview of abstinence measures and rec-
ommendations. Later, West et al. [11] set out criteria and
proposed the Russell standard. It combines a period of
prolonged prevalence/continuous abstinence (six months
or 12 months) after the quit date, during which a partici-
pant is allowed up to 5 cigarettes. This is combined with a
biochemical test, using expired air carbon monoxide.
However, one may argue that the use of carbon monoxide
also has limitations and that self-report is highly accurate
except for high risk groups and medical patients [7]. Des-
pite the proposed Russell standard, studies still use differ-
ent outcome measures, resulting in Cochrane reviews
using different outcomes of abstinence, such as 7-day
point-prevalence abstinence after six months, three-
month prolonged abstinence, and 12-month continuous
abstinence [14, 18]. This clearly illustrates the lack of con-
sensus about an optimal strategy and the need for a study
assessing various views on outcome criteria, identifying
where there is consensus.
Moreover, economic evaluations identify which and to
what extent cessation interventions are cost-effective.
This information may be valuable for decision-makers to
prioritize the reimbursement of interventions. However,
the effectiveness of interventions used in these analyses
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is based on different outcomes of abstinence as well [5,
19]. Hence, despite the existence of the Russell standard,
in order for a standard to be used, consensus on the use-
fulness of the recommendations is also a prerequisite,
consensus that may only partly exist for the Russell
standard. Researchers need more standardisation regard-
ing the measurement of smoking cessation to enhance
interpretations of effectiveness and studies of cost-
effectiveness. Exploring where there is consensus and
where there is lack of consensus is thus important to en-
hance uniformity by adjusting or creating a standard set
of criteria.
To date, no study has investigated the preferences of
smoking cessation researchers and the extent of consen-
sus regarding outcome criteria in randomized controlled
smoking cessation trials. This study explored to what
extent smoking cessation experts agree on the most im-
portant outcome criteria in RCTs. Consensus in out-
come criteria, and thus deciding to use these outcome
criteria, may enhance the comparability of future studies.
Hence, the aim of the study is (1) to provide an overview
of researchers’ opinions regarding the preferred outcome
criteria (i.e. outcome measure, duration of abstinence or
assessment method, and ideal follow-up) to be consid-
ered in smoking cessation RCTs, and (2) to identify the
extent to which researchers have consensus on the im-
portance of these outcome criteria. The results will re-
veal to what extent expert opinions are in agreement
with the current Russell standard, and may indicate
other potentially important outcome measures that
should be considered.
Method
A three-round online Delphi study was conducted
among smoking cessation researchers using Formdesk®
and Qualtrics® between July 2015 and April 2016. Three
iterations are often sufficient to collect the needed infor-
mation and to elicit consensus [20, 21]. The Delphi tech-
nique is a widely used and accepted method for
achieving convergence of expert opinions [22]. This
technique is a method for consensus-building by using a
series of questionnaires to collect data from experts [22–
26]. In contrast to other data gathering and analysis
techniques, the Delphi technique employs multiple itera-
tions [27] in which the feedback process allows and en-
courages the selected experts to reassess their initial
judgments about the information from previous itera-
tions. Moreover, the Delphi technique is characterized
by its ability to provide anonymity to respondents, a
controlled feedback process, and the suitability of a var-
iety of statistical analysis techniques to interpret the data
[23, 26]. These characteristics reduce the effects of dom-
inant individuals and certain downsides of group dynam-
ics, such as manipulation or coercion to adopt or
conform to a certain viewpoint [23, 26]. Furthermore,
the Delphi methodology is practical, as experts from dif-
ferent parts of the world can be included due to its
online character, and experts can complete each ques-
tionnaire at their own convenience, mitigating difficul-
ties from non-matching schedules [26].
Smoking cessation researchers of RCTs were selected
as experts for this study (described in the Delphi
rounds). Experts were recruited via an e-mail, inviting
the researchers to participate in an online Delphi study.
Additionally, participants in the first round were asked
to suggest relevant researchers for the second and third
rounds. For non-responders, an e-mail reminder was
sent after two weeks, followed by another reminder after
approximately four weeks. During each round, the re-
searchers were invited to respond to specific questions
in an online survey. Each survey took about 10–20 min
to complete, and rounds were iterative in nature. In this
study, for each outcome criteria, abstinence of smoking
is defined as having smoked no cigarettes at all during
the specified period of time.
First round
Smoking cessation researchers of RCTs were selected as
experts for this study. In our systematic search for ex-
perts, we used the PubMed database for authors of rele-
vant papers. We filtered for English language papers
from the last 10 years and relied on the following key-
words: ‘smoking cessation AND RCT’, ‘smoking cessation
AND randomized controlled trial’ and ‘smoking cessa-
tion AND randomized controlled trial’. Titles were
screened for relevance, and when author information
was available, all authors of these studies were selected
for recruitment. In addition, experts were identified via
Google Scholar search and the international network of
the authors. The Google Scholar search was a scoping
search using a similar search strategy as the PubMed
database search, to make sure key smoking cessation re-
searchers were included. This led to a list of 250 experts
(randomized using Microsoft Excel® (via the RAND()
function)), from which we invited a random sample of
experts to participate in all three rounds of the Delphi
study. We initially invited 30 experts to participate. Two
weeks later, we invited 14 more experts (thus inviting 44
in total) to reach a sufficient number of participants, as
we wanted to include at least 15 experts in the first
round. This resulted in 17 participating experts (38.6%
response rate) from seven countries (i.e. United States
(US), Hong Kong, United Kingdom (UK), Germany,
Sweden, Australia, and the Netherlands) for the first-
round questionnaire. This number was deemed suffi-
cient, as 10 to 15 experts are regarded as sufficient if the
experts’ backgrounds are rather homogeneous [28]. As
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described by Ludwig [29], 15 to 20 participants have
been used in the majority of Delphi studies.
In the first round, we collected the most important
smoking cessation measures by means of open-ended
questions. The survey consisted of two parts. First, ex-
perts were asked to answer a few items regarding demo-
graphic characteristics: gender (male, female), age, and
current profession (post-doc researcher, assistant profes-
sor, associate professor, professor, senior researcher, and
other). Second, open-ended questions were categorized
around two themes: self-reported outcome measures
and biochemical validation methods. For self-reported
outcome measures we asked the following question:
“What are according to you the most important self-
reported outcome measures to assess smoking cessation
in randomized controlled smoking cessation trials?” In
the survey, there was a limitation of six answers to
stimulate reporting of the most important criteria.
Experts were asked to name the outcome measure (e.g.
prolonged abstinence), its duration of abstinence (e.g. six
months), and the ideal follow-up period (e.g. 6 and
12 months). For biochemical validation methods, the fol-
lowing question was addressed: “What are according to
you the most important biochemical validation methods
to assess smoking cessation in randomized controlled
smoking cessation trials?” Experts were asked to name
the outcome measure of the validation method (e.g. co-
tinine) and its assessment method (e.g. saliva samples).
Additionally, they were asked to indicate for each out-
come measure (i.e. both self-report and biochemical val-
idation measures) that they reported whether there is a
specific research population for which this measure
would be inappropriate. Finally, experts were asked
whether they had other comments and suggestions for
smoking cessation experts for the following rounds of
the present Delphi study.
The collected responses resulted in a list of smoking
cessation measures that were indicated to be most im-
portant in randomized smoking cessation trials. Two re-
searchers analysed this list of measures and where
possible, merged measures that were semantically simi-
lar. After discussion with one more researcher, all three
researchers fully agreed about the measures that were
included in the second-round questionnaire.
Second round
All 250 identified experts, plus researchers suggested by
first round participants, were invited to participate in
the second round. Of the 256 invited experts, 48 from
16 countries (i.e. Australia, France, UK, Canada, China,
Germany, Greece, India, Israel, Italy, Malaysia, New Zea-
land, the Netherlands, Turkey, UK, and the US) com-
pleted the questionnaire, resulting in a 19% response
rate. Experts were presented with a list of smoking
cessation measures that were identified as most import-
ant in randomized smoking cessation trials during the
first round. Then experts were asked to rate the factors
in order of importance using a 7-point Likert scale ran-
ging from 1 (not at all important) to 7 (extremely im-
portant). Factors such as outcome measures, abstinence
duration/assessment method, and ideal follow-up period
were evaluated. The survey assessed the ratings for self-
report outcome measures, biochemical outcome mea-
sures, and ideal follow-up separately. For self-report and
biochemical outcome measures, first the outcome mea-
sures were rated, which was then followed by the ideal
abstinence duration per measure. Experts rated all fac-
tors due to forced response in the survey. To analyse the
importance of each factor, the median score (Mdn) was
calculated and a score of ≥6 was considered important
(i.e. agreement with the factor being important) [30]. To
gain an indication of the degree of consensus between
experts on the factors, interquartile ranges (IQR) were
calculated [30]. Using a 7-point Likert scale, IQRs with a
value of ≤1 (i.e. more than half of the opinions fall
within one point of the scale) indicate good consensus
among the experts [24].
Third round
Factors with IQRs of ≤1 were removed from the ques-
tionnaire for the third round. All experts from the sec-
ond round were invited to re-rate the remaining factors
for which there was no consensus. Again, experts rated
all factors due to forced response in the survey. Of 48
invited experts, 37 experts from 12 countries (i.e.
Australia, UK, Canada, China, Germany, Greece, India,
Israel, Malaysia, New Zealand, the Netherlands, and the
US) completed the questionnaire in this final round
(77% response rate). For each factor in the third round
questionnaire, the Mdn and IQR of the second round
were presented alongside the question to re-rank the
remaining factors/outcome measures on their
importance.
Results
In the first round, 86 unique factors were identified by
17 experts, grouped by self-report outcome measures
(24 factors), biochemical validation methods (16 factors),
combinations of outcome measures (37 factors), and the
ideal follow-up periods (nine factors). In the second
round, experts reached consensus (IQRs ≤1) on eight
factors that were considered important (Mdn ≥ 6) (i.e.
five factors for self-report outcome measures, two fac-
tors for biochemical validation methods, and one for the
ideal follow-up periods). In the third round, experts
reached consensus on 12 additional factors that were
considered important (i.e. four for self-report outcome
measures, two for biochemical validation methods, and
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4 for the ideal follow-up periods). In the third round, it
was revealed that there was consensus among experts that
biochemical validation should not always be used to valid-
ate self-report smoking cessation measures (Mdn = 5, IQR
= 1). In total, from all factors, experts reached consensus
on 77 factors (90%), of which 20 factors were considered
important (23%). The unique factors and results of
the second and third rounds are depicted in Tables 1,
2, and 3.
Self-reported outcome measures
After the third round, experts reached consensus on four
important self-reported outcome measures (point-preva-
lence abstinence, number of cigarettes smoked, continu-
ous abstinence, and prolonged abstinence) and five
related abstinence periods (see Table 1).. The median
score for prolonged abstinence was higher than the
other outcome measures, indicating higher importance.
We revealed for point-prevalence abstinence that the
important duration of abstinence was past seven days.
Moreover, the number of cigarettes for the past seven
days was deemed important as well. For continuous ab-
stinence, past 30 days and past six months were both
considered important, although past six months had a
higher median score. For prolonged abstinence, the past
six months and past 12 months were important, al-
though here the past six months had a higher median
score as well. No consensus was reached for the most
important grace period for prolonged abstinence.
Biochemical validation methods
Experts reached consensus that biochemical validation
methods should not always be used to validate self-
report smoking cessation measures (Mdn = 5, IQR = 1).
In total, experts reached consensus on four important
biochemical validation methods (see Table 2), with car-
bon monoxide and cotinine being important validation
methods. For carbon monoxide, expired air samples
were the preferred assessment method. Saliva samples
were the most preferred assessment method for cotinine.
Table 1 Importance and consensus on self-reported outcome measures (R2: n = 48, R3: n = 37)
Factors R2: Mdn R2: IQR R3: Mdn R3: IQR
Number of cigarettes smoked (past 24 h) 5.00 2.00 5.00 1.00
Number of cigarettes smoked (past 7 days)a 6.00 2.00 6.00 1.00
Quit attempts during past 7 days 4.00 2.00 4.00 1.00
Quit attempts past month 5.00 2.00 5.00 1.00
Point-prevalence abstinencea 6.00 2.00 6.00 1.00
• Past 24 h 5.00 3.00 5.00 1.00
• Past 7 daysa 6.00 2.00 6.00 1.00
• Past 30 days 5.00 2.00 5.00 1.00
• Past 2 months 4.00 2.00 4.00 1.00
• Past 3 months 4.00 2.00 4.00 1.00
Continuous abstinencea 6.00 1.00 – –
• Past 30 daysa 6.00 2.00 6.00 1.00
• Past 2 months 5.00 2.00 5.00 1.00
• Past 3 months 5.00 2.00 5.00 0.00
• Past 6 monthsa 6.50 1.00 – –
• Past 12 months 6.00 2.00 6.00 2.00
Prolonged abstinencea 7.00 1.00 – –
• Past 30 days 5.00 2.00 5.00 1.00
• Past 2 months 4.50 1.00 – –
• Past 3 months 5.00 2.00 5.00 1.00
• Past 6 monthsa 7.00 1.00 – –
• Past 12 monthsa 6.50 1.00 – –
Grace period:
• 1 week, duration at the start of the quit attempt (grace period) 5.00 2.00 5.00 1.00
• 2 weeks, duration at the start of the quit attempt (grace period) 5.00 2.00 5.00 2.00
Mdn median score, IQR interquartile range
a = Consensus (IQRs ≤1) on important items (Mdn ≥ 6)
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Experts reached consensus that thiocyanate is not an im-
portant biochemical validation method.
Ideal duration of follow-up periods
Experts reached consensus on five important factors
regarding the ideal duration of follow-up periods (see
Table 3); six months, 12 months, six months with inter-
mediate measurements, 12 months with intermediate
measurements, and six and 12 months. It seems that
there was a higher consensus among experts regarding a
follow-up of 12 months and a follow-up of six and
12 months (IQR = 0), compared to the other follow-up
periods.
Discussion
Findings regarding expert opinion
In order to enhance comparability of studies, this study
attempted to provide an overview of researchers’ top
preferences and the consensus among researchers re-
garding the outcome criteria to be considered in ran-
domized controlled smoking cessation trials.
With regard to the most important self-report out-
come measure, our results show that researchers
reached consensus that point prevalence abstinence,
continuous abstinence, and prolonged abstinence are all
important; each method having its own strengths and
limitations as reported in the literature [8]). However,
prolonged abstinence seems to be the most preferred
Table 2 Importance and consensus on biochemical validation methods (R2: n = 48, R3: n = 37)
Factors R2: Mdn R2: IQR R3: Mdn R3: IQR
Anabasine, using urine samples 4.00 2.00 4.00 2.00
Carbon monoxidea 6.00 3.00 6.00 1.00
The assessment method to detect carbon monoxide:
• Expired air samplesa 6.00 2.00 6.00 1.00
• Blood samples 4.00 3.00 4.00 1.00
Cotininea 6.00 1.00 – –
• Saliva samplesa 6.00 1.00 – –
• Urine samples 5.00 2.00 5.00 1.00
• Blood samples 4.00 2.00 4.00 0.00
• Hair samples 4.00 2.00 4.00 1.00
• Plasma samples 4.00 2.00 4.00 1.00
• Serum samples 4.00 1.00 – –
Thiocyanate 4.00 2.00 4.00 1.00
The assessment method to detect thiocyanate: 4.00 1.00
• Plasma samples 4.00 1.00 – –
• Saliva samples 4.00 1.00 – –
• Urine samples 4.00 2.00 4.00 0.00
Mdn median score, IQR interquartile range
a = Consensus (IQRs ≤1) on important items (Mdn ≥ 6)
Table 3 Importance and consensus on duration of follow-up periods
Factors R2: Mdn R2: IQR R3: Mdn R3: IQR
At the set quit date or the end of a grace period: 4.00 3.00 4.00 1.00
Follow-up for 30 days 5.00 2.00 5.00 1.00
Follow-up for 3 months 5.00 2.00 5.00 1.00
Follow-up for 6 monthsa 6.00 2.00 6.00 1.00
Follow-up for 12 monthsa 6.00 2.00 6.00 0.00
Follow-up for 3 months with intermediate measurements 4.50 1.00 – –
Follow-up for 6 months with intermediate measurementsa 6.00 1.00 – –
Follow-up for 12 months with intermediate measurementsa 6.00 2.00 6.00 1.00
Follow-ups for 6 and 12 monthsa 6.00 2.00 6.00 0.00
Mdn median score, IQR interquartile range
aConsensus (IQRs ≤1) on important items (Mdn ≥ 6)
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outcome measure, especially six-month prolonged ab-
stinence. Consensus on the grace period was not
reached. Moreover, a seven-day point-prevalence abstin-
ence and a 30-day or six-month continuous abstinence
outcome measure were also regarded as important. Re-
garding the follow-up, results reflect that our respon-
dents regarded six month or 12 month follow-up as
most important.
For the usage of a standard, consensus on the useful-
ness of the recommendations is a prerequisite, which
may only partly exist for the Russell standard. This study
therefore sheds light on where expert opinion may differ
from this standard (see Table 4). First, findings indicate
the importance of including six-month prolonged ab-
stinence, which is consistent with the Russell standard
[11]. However, in contrast with the Russell standard, re-
sults showed that our respondents also deemed seven-
day point-prevalence abstinence, six-month continuous
abstinence, and number of cigarettes smoked after seven
days important to include in a trial. It is not clear from
this study whether these measures—regarded as impor-
tant—should be used complementarily or alternatively.
However results seem in line with recommendations
from Hughes and colleagues (2003 [16]; 2010 [15]) to re-
port prolonged abstinence as the preferred measure and
point-prevalence abstinence as a secondary measure.
These two measures complement each other as pro-
longed abstinence is more stable and a better indicator
for lifelong abstinence and health benefit, while point-
prevalence abstinence may suffer less from memory bias
and missing data, and also detects delayed quitting [7,
16]. Consistent with the Russell standard, the ideal grace
period remained undefined [16].
Second, concerning the use of biochemical validation
methods our respondents indicated that they are not
always needed in smoking cessation RCTs. Hence, this
may differ from the Russell standard (see Table 4), in
which a biochemical validation with carbon monoxide
is recommended [11]. It is yet unclear under which
conditions these biochemical validation methods are
regarded as important by the researchers to support
self-report outcomes. The SRNT Subcommittee on
Biochemical Verification (2002), provides some guid-
ance and recommends using biochemical validations in
most new product and all harm-reduction studies, with
the exception of circumstances where its use is not de-
sirable or feasible, such as online data gathering [9].
When including biochemical validation methods, find-
ings suggest that carbon monoxide (using expired air
samples) and cotinine (using saliva samples) are most
important. This is only partly consistent with recom-
mendations from the Russell standard. Findings thus
indicate that cotinine was viewed as an important bio-
chemical measure to validate smoking-related out-
comes [31]. Both measures have their strengths and
limitations, with cotinine having superior sensitivity
and specificity, while carbon monoxide is easily
assessed, detects smoking and not non-combustible
forms of nicotine delivery (e.g. nicotine replacement
therapy), and does not require storing body fluids sam-
ples [7, 11].These biochemical validation methods are
limited in that they may only indicate point prevalence
abstinence due to their short half-life [9]. Consistent
with the literature, findings show that experts deem
thiocyanate of lesser importance in trials because it has
inadequate sensitivity and specificity [7]. A systematic
review of the literature showed that self-reports may
underestimate true smoking prevalence [31]. Hence,
studies benefit from biochemical verification as it pro-
vides an objective alternative to reported estimates.
Table 4 Recommendations compared to the Russell standard
Russell standard Findings Recommendations (Russell 2.0)
Self-report Prolonged
abstinence
Over the whole follow-up
period
Prolonged abstinence 6 or/and
12 months




7 daysa Point prevalence
abstinence
7 daysa
Continuous abstinence 6 monthsa
Number of cigarettes
smoked
7 daysa Number of cigarettes
smoked
7 daysa





(9 p.p.m. in) expired air Carbon monoxide expired air
Cotinineb salivaa Cotinineb (15 ng/ml in)
salivaa




aDifferent from the Russell standard
bUse biochemical validation in new product and harm-reduction studies
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Last, according to the experts, the ideal duration of
follow-up is six and/or 12 months, with or without inter-
mediate measurements. Hence, follow-up should span a
minimum of six months. This is consistent with the
Russell standard (see Table 4), which recommends a
follow-up of 6 or 12 months from the target quit date or
the end of a predefined ‘grace period’ [11].Others also
recommend tying all follow-ups to the quit date and
reporting on 6- and/or 12-month abstinence rates [16].
Recommendations (Russell 2.0)
This study showed that that there is consensus that
some outcome measures may not be viable options for
most smoking cessation RCT’s (e.g. 2-month point-
prevalence abstinence), and that some measures may be
important to consider (e.g. six-month prolonged abstin-
ence and seven-day point-prevalence abstinence).
Discussion is needed about whether more uniform
measurement is possible by developing a new standard
or adjusting the Russell standard, consistent with expert
preferences. The authors of the Russell standard men-
tioned that in time, due to experience, the standard may
need revisions [11]. This study yielded findings that sug-
gest considering more outcome criteria in smoking
cessation RCTs (compared to the Russell standard) (see
Table 4).
As multiple considerations are mentioned, researchers
may be bewildered by the array of options in measuring
smoking cessation. These findings may then not enhance
uniformity. Hence, based on the stated preferences of
this Delphi panel and literature on outcome criteria, we
provide several recommendations, supporting the prop-
osition of an adapted Russell standard (Russell 2.0) (see
Table 4). First, next to the prolonged abstinence (with a
follow-up of 6 and/or 12 months), we suggest including
7-day point-prevalence abstinence, while assessing the
number of cigarettes smoked in the past seven days for
those who are not abstinent. The 7-day point-prevalence
abstinence may be viewed as to some extent measuring
a different construct than 6-month prolonged abstinence
[8]. From that viewpoint, to assess smoking cessation
one needs to include both prolonged abstinence and 7-
day point-prevalence abstinence. These two measures
complement each other. Prolonged abstinence is more
stable and a better indicator of lifelong abstinence and
health, while point-prevalence abstinence may suffer less
from memory bias and missing data. Point-prevalence
abstinence also detects delayed quitting, including re-
lapsed smokers who decided to continue to quit smok-
ing after relapse (thus reflecting the dynamic process of
quitting, in contrast to continuous abstinence) [7, 16].
To define an ideal grace period (as this is unclear based
on our findings), a recommendation of 2-weeks may be
used [16]. When a prolonged abstinence measure is
included, we suggest omitting continuous abstinence as
only a small minority of smokers actually change in a
linear manner—from smoking to non-smoking—without
experiencing any lapses or relapses [8, 32]. Second, we
recommend using biochemical validation at least in a
sample of the population. We argue that carbon monox-
ide may not be the preferable biomarker as it may be
highly vulnerable to environmental influences, especially
in light smokers (who have relatively low levels of car-
bon monoxide related to tobacco use). Instead, we found
that cotinine is a preferable biomarker due to its super-
ior sensitivity and specificity (not influenced by diet and
pollution exposure) [9]. When using cotinine, literature
suggests that the preferred cut-off point used in cotinine
is 15 ng/ml (85 nmol/L) in saliva [9]. When cotinine is
used, it must be stressed that it is important to assess
the presence of other forms of nicotine including nico-
tine replacement therapy and extensive exposure to
second-hand smoke [9]. Hence, we recommend consid-
ering cotinine; if this is not possible, carbon monoxide
would be the preferred second option [9, 31]. As men-
tioned, and in line with the Russell standard, we suggest
that the ideal follow-up include at least a 6-month
follow-up, with preferably an additional 12-month
follow-up to show long-term (and thus more stable)
abstinence.
Limitations
We recognize that this Delphi study has its limitations.
First, one limitation is that we could not take into
account specific requirements that may have to be
addressed by a specific RCT; it is obvious that such
requirements also influence the selection process of the
most important outcome parameters. This study did not
aim to suggest a universal outcome that applies in all
smoking cessation trials. Moreover, our findings clearly
reveal a need to consider more outcome criteria than
those suggested by the Russell standard. As with the
Russell standard, it is expected that these outcome cri-
teria are most applicable in trials with face-to-face as-
sessments with smokers that include a designated quit
date [11]. When there is lack of face-to-face contact,
biochemical validation may be difficult or inappropriate
to conduct. However, in some studies without face-to-
face contact, biochemical validation was still conducted,
for instance using test strips to measure cotinine in sal-
iva [33]. The advantage of using clear standards is that
the comparison of study outcomes will be enhanced.
Our results, however, reveal a tension between this need
and the needs of researchers to best characterize the ef-
fects of their treatments, as more outcome measures
were suggested than identified in the Russell standard.
Second, it is unclear to what extent these factors are
ranked by relative importance and which measures
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should be included in RCTs next to each other. The
same reasoning applies to factors where no consensus
was reached. It is not clear to what extent these factors
are less important to consider (e.g. a Mdn of 5 may indi-
cate that a certain factor is important in some situations
but not all). Perhaps for these factors, the importance
depends on the situation, and consensus may only be
reached if the conditions are specified. In healthcare re-
search, studies are increasingly using conjoint analyses
(e.g. discrete choice experiments and best-worst scaling
surveys), which may provide opportunities to shed light
on the relative importance of our findings [34, 35].
Third, another limitation is that this study may suffer
from non-response bias, which may lead to limited
generalizability. However, this qualitative study is ex-
plorative in nature, and the non-response rates were not
exceptional as unsolicited questionnaires were used [36].
However this study cannot rule out selection bias of ex-
perts with a deviant opinion regarding the outcome cri-
teria. The possibility remains that experts with a deviant
opinion may feel more inclined to report on their views,
a bias that most studies may encounter. Moreover, as we
filtered for English articles in search of experts, this
study is prone to selection bias for smoking cessation
experts. Further research may be needed to assess the
external validity of our findings, suggesting that the
Russell standard may not be sufficient in many trials.
Therefore, it is important to consider more outcome cri-
teria. Fourth, selection bias of participants as experts
may have occurred as selection was based on the author-
ship of relevant papers. However in the recruitment
process we made explicit the goal of this study and our
interest for input from smoking cessation experts. It is
conceivable that most researchers receiving this e-mail
did not participate because they did not feel they were
smoking cessation experts. This may also explain the
(rather high) dropout rate. Moreover, we checked the list
of participants and concluded that important smoking
cessation experts had participated. Last, besides the im-
portance of using (a set of ) comparable outcome mea-
sures, guidelines for addressing missing values are highly
important as well. Complete case analysis has been re-
placed by penalized imputation (“missing = smoking”),
but that may produce estimates that are too conserva-
tive, requiring more advanced strategies, such as mul-
tiple imputation [37].
Conclusions
The findings suggest that regarding expert opinion, only
partial compliance with the Russell standard is reported
by experts, which is congruent with the reports of effi-
cacy studies. Experts seem to deem more outcome cri-
teria important for consideration in randomized
controlled smoking cessation trials. Consequently,
findings suggest the need to develop an adapted version,
a Russell 2.0 standard, that includes more outcome mea-
sures, such as: (1) six-month prolonged abstinence (or
continuous abstinence); (2) seven-day point-prevalence
abstinence with the numbers of cigarettes smoked in
these seven days; (3) biochemical validation, at least in a
sample of the population, with a preference for cotinine
assessments over carbon monoxide because of its greater
sensitivity and specificity; (4) follow-ups after 6 months,
and preferably also after 12 months.
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